Granted Patent B2

US 12,741,019 · App. 19/455,921 · Granted Sep 22, 2026

Inventors: Andrea Carfi (Cambridge, MA); Guillaume Stewart-Jones (Cambridge, MA); Hamilton Bennett (Cambridge, MA); Kai Wu (Cambridge, MA); Darin Edwards (Cambridge, MA); Gwo-Yu Chuang (Cambridge, MA); David Reid (Cambridge, MA)

Assignee: ModernaTX, Inc.

A61K39/215A61P31/14C07K14/005A61K2039/53A61K2039/545A61K2039/70C12N2770/20034

Abstract

Claims (14)

1 . A pharmaceutical composition comprising a messenger RNA (mRNA) comprising a nucleotide sequence encoding an immunogenic SARS-COV-2 Spike(S) protein, wherein the SARS-COV-2 S protein comprises: (a) at least 10 of the following mutations: A69-70, T951, G142D, ΔY144, R190S, K417N, N439K, E484K, S477N, T478K, N501Y, D614G, H655Y, and P681H, wherein said numbering is based upon the SARS-CoV-2 S protein set forth in SEQ ID NO:20; and (b) an amino acid sequence that is at least 97% identical to SEQ ID NO:14, or to an immunogenic fragment thereof; wherein the mRNA is formulated in lipid nanoparticles, and wherein the mRNA comprises a 5′-cap, a 5′-UTR, a 3′-UTR, a poly(A) sequence, and 1-methyl-pseudouridine substitutions at one or more uridine positions of the mRNA.

2 . The pharmaceutical composition of claim 1 , wherein the nucleotide sequence is at least 90% identical to SEQ ID NO:13.

3 . The pharmaceutical composition of claim 1 , wherein the nucleotide sequence is at least about 90% identical to SEQ ID NO:13.

4 . The pharmaceutical composition of claim 1 , wherein the mRNA comprises 1-methyl-pseudouridine substitutions at all uridine positions of the nucleotide sequence.

5 . The pharmaceutical composition of claim 1 , wherein the mRNA is present in an amount within a range of about 25 μg to about 100 μg.

6 . The pharmaceutical composition of claim 1 , wherein the mRNA is present in an amount of about 10 μg.

7 . The pharmaceutical composition of claim 1 , wherein the mRNA is present in an amount of about 30 μg.

8 . A method of eliciting an immune response against SARS-COV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 1 in an effective amount to induce the immune response.

9 . A method of eliciting an immune response against SARS-COV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 2 in an effective amount to induce the immune response.

10 . A method of eliciting an immune response against SARS-COV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 3 in an effective amount to induce the immune response.

11 . A method of eliciting an immune response against SARS-COV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 4 in an effective amount to induce the immune response.

12 . A method of eliciting an immune response against SARS-COV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 5 in an effective amount to induce the immune response.

13 . A method of eliciting an immune response against SARS-COV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 6 in an effective amount to induce the immune response.

14 . A method of eliciting an immune response against SARS-COV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 7 in an effective amount to induce the immune response.

Assignments (1)

Continuity (12)

References Cited (400)